DeepMed Research

Nifedipine

Generic Name: Nifedipine

Brand Names: Adalat, Afeditab CR, Nifediac, Nifedical, Procardia

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈N_₂O_₆

CAS Number: 21829-25-4

Unique Ingredient Identifier: I9ZF7L6G2L

Background: Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is amlodipine.

Nifedipine was granted FDA approval on 31 December 1981.

Indication: Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.

Associated Conditions: Achalasia, Chronic Stable Angina Pectoris, Fissure;Anal, Hypertension, Hypertensive Emergency, Premature Labour, Proctalgia, Pulmonary Edemas, Pulmonary Hypertension (PH), Raynaud's Phenomenon, Ureteral Calculus, Vasospastic Angina

Clinical Trials

Vaginal Indomethacin for Preterm Labor

Phase 2

Not yet recruiting

Conditions: Obstetric Labor, Premature

Interventions: Drug: Indomethacin
Drug: Nifedipine

First Posted Date: 2020-05-27

Last Posted Date: 2020-08-11

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 300

Registration Number: NCT04404686

Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor

Phase 4

Completed

Conditions: Preeclampsia Severe

Interventions: Drug: Nifedipine 30 MG
Drug: Placebos

First Posted Date: 2020-05-18

Last Posted Date: 2023-07-24

Lead Sponsor: Ohio State University

Target Recruit Count: 110

Registration Number: NCT04392375

Locations: 🇺🇸
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States

Persistent Postpartum Hypertension Pilot Trial

Phase 4

Terminated

Conditions: Hypertension in Pregnancy

Interventions: Drug: Nifedipine Extended-Release Tablets

First Posted Date: 2020-04-16

Last Posted Date: 2023-04-03

Lead Sponsor: Duke University

Target Recruit Count: 12

Registration Number: NCT04349124

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States

Preeclampsia Postpartum Antihypertensive Treatment

Phase 3

Recruiting

Conditions: Hypertension in Pregnancy
Preeclampsia

Interventions: Drug: Labetalol, Nifedipine

First Posted Date: 2020-03-06

Last Posted Date: 2024-11-26

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 300

Registration Number: NCT04298034

Locations: 🇺🇸
Medical College of Wisconsin-Froedtert Hospital, Milwaukee, Wisconsin, United States

Non-Invasive Positive Pressure Ventilation Management of High Altitude Pulmonary Edema

Not Applicable

Conditions: High Altitude Pulmonary Edema
Non-Invasive Positive Pressure Ventilation
Hypoxia

Interventions: Device: Non-Invasive Positive Pressure Ventilation
Drug: Nifedipine
Other: supplemental oxygen

First Posted Date: 2020-02-28

Last Posted Date: 2020-09-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 16

Registration Number: NCT04288219

Locations: 🇳🇵
Himalayan Rescue Association, Kathmandu, Nepal

Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period

Phase 4

Completed

Conditions: Hypertension in Pregnancy
Gestational Hypertension
Preeclampsia Severe
Postpartum Preeclampsia
Postpartum

Interventions: Drug: NIFEdipine ER
Drug: Enalapril

First Posted Date: 2020-01-22

Last Posted Date: 2022-11-30

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 94

Registration Number: NCT04236258

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Evaluating the Utility of Continuous Positive Airway Pressure in the Treatment of High Altitude Pulmonary Edema

Not Applicable

Completed

Conditions: Continuous Positive Airway Pressure
High Altitude Pulmonary Edema

Interventions: Device: CPAP mask system
Drug: Nifedipine 30 MG
Device: CPAP mask system without PEEP

First Posted Date: 2019-12-05

Last Posted Date: 2024-02-07

Lead Sponsor: CommonSpirit Health

Target Recruit Count: 64

Registration Number: NCT04186598

Locations: 🇺🇸
Breckenridge Medical Center, Breckenridge, Colorado, United States

Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation

Phase 3

Recruiting

Conditions: Preterm Premature Rupture of Membrane

Interventions: Drug: Placebo of Nifedipine
Drug: Nifedipine

First Posted Date: 2019-06-05

Last Posted Date: 2024-02-13

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 850

Registration Number: NCT03976063

Locations: 🇫🇷
Trousseau University Hospital, Paris, France

Treating Postictal Symptoms Using Ibuprofen and Nifedipine

Phase 2

Recruiting

Conditions: Epilepsy
Epilepsies, Partial

Interventions: Drug: Placebo
Drug: Ibuprofen
Drug: Nifedipine

First Posted Date: 2019-05-14

Last Posted Date: 2024-05-09

Lead Sponsor: University of Calgary

Target Recruit Count: 90

Registration Number: NCT03949478

Locations: 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦
South Health Campus, Calgary, Alberta, Canada

Genetic Polymorphisms of ABCG2/BCRP on the Transport of Nifedipine to Breast Milk.

Phase 4

Conditions: Drug Transporter

Interventions: Procedure: Blood and breast milk sampling
Drug: Nifedipine

First Posted Date: 2018-10-18

Last Posted Date: 2018-10-18

Lead Sponsor: Natalia Valadares de Moraes

Target Recruit Count: 19

Registration Number: NCT03710395

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy